| 6133 |
Safety profile of BCG Vaccine |
02/06/2024 |
TB Vaccines |
| 2628 |
Sequence of Using Replacement Drugs to Modify the Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1869 |
Management of DR-TB ADR: QT Prolongation |
02/06/2024 |
DR-TB and PMDT |
| 1870 |
Management of ADR: Rash, Allergy and Anaphylaxis Reaction |
02/06/2024 |
DR-TB and PMDT |
| 1871 |
Management of DR-TB ADR: Hepatitis |
02/06/2024 |
DR-TB and PMDT |
| 1873 |
Management of DR-TB ADR: Vestibular Toxicity |
02/06/2024 |
DR-TB and PMDT |
| 1874 |
Management of DR-TB ADR: Optic Neuritis |
02/06/2024 |
DR-TB and PMDT |
| 1875 |
Management of DR-TB ADR: Electrolyte Disturbances |
02/06/2024 |
DR-TB and PMDT |
| 1876 |
Management of DR-TB ADR: Alopecia |
02/06/2024 |
DR-TB and PMDT |
| 1877 |
Management of DR-TB ADR: Superficial Fungal Infection and Thrush |
02/06/2024 |
DR-TB and PMDT |
| 1878 |
Management of DR-TB ADR: Lactic Acidosis |
02/06/2024 |
DR-TB and PMDT |
| 1879 |
Management of DR-TB ADR: Dysglycaemia and Hyperglycemia |
02/06/2024 |
DR-TB and PMDT |
| 1880 |
Access to New Regimens to Patients Seeking Care in Private/Other Sectors |
02/06/2024 |
DR-TB and PMDT |
| 1907 |
Active TB Drug Safety Monitoring [aDSM] |
02/06/2024 |
DR-TB and PMDT |
| 6341 |
Adult BCG Vaccination- Preparatory Activities |
02/06/2024 |
|
| 6339 |
Adult BCG Vaccination- Study Population : Exclusion Criteria |
02/06/2024 |
|
| 6345 |
Adult BCG Vaccination- Monitoring and Statistical Analysis Plan for Impact on TB Notification |
02/06/2024 |
|
| 6343 |
Adult BCG Vaccination- Beneficiary Consent for Adult BCG Vaccination |
02/06/2024 |
|
| 6340 |
Adult BCG Vaccination- Special consideration for Adult BCG vaccination |
02/06/2024 |
|
| 6344 |
Adult BCG Vaccination- Monitoring and Safety Evaluation Plan |
02/06/2024 |
|
| 6342 |
Adult BCG Vaccination- Ethical Consideration |
02/06/2024 |
|
| 1909 |
Adverse Event Definitions and Classifications |
02/06/2024 |
DR-TB and PMDT |
| 1997 |
Diagnostic Algorithm for Paediatric DR-TB |
02/06/2024 |
DR-TB and PMDT |
| 2039 |
Use of M/XDR-TB Regimen in Pre-existing liver disease |
02/06/2024 |
DR-TB and PMDT |
| 2616 |
Reporting of Adverse Events and Serious Adverse Events |
02/06/2024 |
DR-TB and PMDT |
| 2618 |
Goals of DR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 2620 |
Treatment of DR-TB in Children |
02/06/2024 |
DR-TB and PMDT |
| 2623 |
Role of the District Drug Store [DDS] in the Constitution of Patient-wise Boxes |
02/06/2024 |
DR-TB and PMDT |
| 6336 |
Adult BCG Vaccination- Expected Study Outcomes |
02/06/2024 |
TB Vaccines |
| 6337 |
Adult BCG Vaccination-Study settings |
02/06/2024 |
TB Vaccines |
